Amgen, Inc.

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.

The Phase III AALL1731 trial showed Blincyto (blinatumomab) significantly improved three-year disease-free survival (DFS) in pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) when added to chemotherapy, with a 61% decrease in relapse risk. The trial's interim analysis led to early termination due to the observed benefit, highlighting Blincyto's potential as a transformative treatment in this patient population.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but with stricter controls. Biosimilars, including Humira’s, have struggled with adoption despite cost savings potential. Optum Rx also adds and removes various oncology and CNS medications for 2025.

Optum Rx prefers Amgen’s Amjevita over Sandoz’s Hyrimoz and Cyltezo on its 2025 commercial formularies, aiming to reduce costs and improve affordability. Humira remains on the formulary but is subject to prior authorization. Biosimilars have struggled with low adoption despite cost advantages, but large PBMs like CVS Health are shifting towards biosimilars. Optum Rx also adds and removes various oncology and CNS medications from its 2025 formulary.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

BioAge Labs discontinues Phase II STRIDES study of azelaprag in obesity due to safety concerns, specifically liver transaminitis in 11 participants. The decision, though disappointing, prioritizes patient safety. BioAge will analyze STRIDES findings and update plans for azelaprag in Q1 2025.

Iscalimab, a monoclonal antibody targeting an inflammatory pathway in Sjögren’s disease, showed improvements in clinician-reported disease activity and patient-reported dryness and fatigue in a Phase 2b trial, offering hope after prior drug failures.

CD40 targeted therapies, currently in late-stage clinical trials, show promise across various diseases. First approval expected by 2027, with over 20 therapies in development. Key players include Amgen, Sanofi, and GenMab.

CD40 targeted therapies in immunotherapy research focus on the CD40 receptor for treating various diseases, with no approvals yet but promising candidates in late-stage clinical development. First approval expected by 2027, with over 20 therapies in trials. Interest in CD40 targeting expands to cancer, infectious diseases, and neurodegenerative diseases. Antibody therapies dominate, with advanced candidates like Sanofi's Frexalimab and Alligator Bioscience's mitazalimab. Proprietary technologies like GenMab's DuoBody platform facilitate development. Major pharmaceutical companies like Amgen, Sanofi, and GenMab are key players, with collaborations advancing research.